CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Revolution a new overweight at Morgan Stanley on RAS-targeted oncology franchise

Positive
AI Analysis

Summary

Morgan Stanley initiated an overweight rating on Revolution Medicines, citing confidence in its RAS-targeted oncology franchise.

Importance:3/10
Sentiment:
0.70
analyst_ratingoncologyRAS_targetedMorgan_Stanley
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on September 10, 2026 3:49 PM

Read Original